Kisqali on PBS, very few will get it.
those of us who were waiting to get Ibrance or Kisqali on PBS we will not get either. Only newly the diagnosed who have NOT had an Aromatose drug. ( there would be very few of them ) BCNA failed t...
Forum Discussion
Wendy Lou,
That was my first read of the PBS criteria - posted above .
i have been contacted by BCNA and been told they had consulted a Novartis Medical Advisory - and that is not correct women treated with AI in early disease adjuvant setting are eligible.i have since reposted in bold letters as to not cause undue angst.
i remain sad as who is covered and how the ministry made their decision. From Lisa post Mid June and what I have read from PBAC, men were not covered as the evidence was weaker - it will always be weaker it is harder to get the same numbers for studies. Now according to Giovanna it seems that between mid June and 1st of July - outside PBAC ( because I don't think there was a special meeting reported) men are now covered. If that is correct that would be great.
it still leaves three central questions:
1. What about women with HR positive Metastatic disease who have been on AI but where the oncologist feel they would benefit from a CDK?
2. What about the combination of Faslodex and CDK as a second line - study numbers there are very good?
3. Why was Ribociclib chosen over Palbociclib - similar side effects esceot for the potential cardiac complications with Ribociclib, and what about Abemaciclib which has been shown to work as monotherapy in heavily pretreated women with Metastic breast cancer.
We don't talk about this enough - and it is difficult for both patients first and foremost but also clinicians - who are forced to make decisions whether to discuss ALL available options knowing that some will be out of affordability - in this group of patients facing chemo and death.
I think its important to value the effort BCNA continually puts in supporting women with BC - that is their mission - but I would like to see more open conversation about how tough it is to get these treatments in Australia. Be happy about successes but know and admit women have a hell of a fight on their hands to get latest treatments and they are costly on those many grounds. Be respectful of the unthinkably tough process they go through.
On a note of hope trials on CDK 7 and CDK 12 are taking place - albeit phase 1.
That was my first read of the PBS criteria - posted above .
i have been contacted by BCNA and been told they had consulted a Novartis Medical Advisory - and that is not correct women treated with AI in early disease adjuvant setting are eligible.i have since reposted in bold letters as to not cause undue angst.
i remain sad as who is covered and how the ministry made their decision. From Lisa post Mid June and what I have read from PBAC, men were not covered as the evidence was weaker - it will always be weaker it is harder to get the same numbers for studies. Now according to Giovanna it seems that between mid June and 1st of July - outside PBAC ( because I don't think there was a special meeting reported) men are now covered. If that is correct that would be great.
it still leaves three central questions:
1. What about women with HR positive Metastatic disease who have been on AI but where the oncologist feel they would benefit from a CDK?
2. What about the combination of Faslodex and CDK as a second line - study numbers there are very good?
3. Why was Ribociclib chosen over Palbociclib - similar side effects esceot for the potential cardiac complications with Ribociclib, and what about Abemaciclib which has been shown to work as monotherapy in heavily pretreated women with Metastic breast cancer.
We don't talk about this enough - and it is difficult for both patients first and foremost but also clinicians - who are forced to make decisions whether to discuss ALL available options knowing that some will be out of affordability - in this group of patients facing chemo and death.
I think its important to value the effort BCNA continually puts in supporting women with BC - that is their mission - but I would like to see more open conversation about how tough it is to get these treatments in Australia. Be happy about successes but know and admit women have a hell of a fight on their hands to get latest treatments and they are costly on those many grounds. Be respectful of the unthinkably tough process they go through.
On a note of hope trials on CDK 7 and CDK 12 are taking place - albeit phase 1.